A pharmacokinetic study to compare the bioavailability between MK-0663 (etoricoxib ) 120 mg Tablets from Two Different Manufacturing Sites (Frosst Iberica, Spain versus Elkton, VA, USA).

Completed

• Conditions: arthrosis; rheumatism; 10023213

• Registration Number: NL-OMON37397
• Lead Sponsor: Merck Sharp & Dohme (MSD)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

Male and female, between 18-55 years of age, BMI 18-30.

Exclusion Criteria

Clinical significant abnormalities at medical research

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To determine the relative bioavailability of etoricoxib 120 mg tablets<br /><br>manufactured at Frosst Iberica, Spain and Elkton, VA, USA.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To evaluate the safety and tolerability of a single dose of 120 mg etoricoxib<br /><br>manufactured at Frosst Iberica, Spain and Elkton, VA, USA, in healthy adults.</p><br>